
Apidra 100 Iu/ml 3 ml Cartridge
Salt Composition: Insulin Glulisine (100IU)
Expiry Date: 01/2028
Inclusive of all taxes
5 Cartridge
About The Product
Fast-acting insulin used before meals.
Description
Apidra 100 lu/ ml 3 ml cartridge is a a rapid acting insulin, used to control blood sugar in patient with type 1 and type 2 diabetes mellitus. The medication active ingredient is Insulin Glulisine (100IU).
It acts by facilitating cellular glucose uptake, primarily in muscle and adiptose tissues and inhibiting hepatic glucose production, thereby lowering blood glucose level. This prescription based medication should be used under the guidance of a healthcare professional and follow strict timings to ensure safety of the treatment.
Indication
Maintaining blood sugar level
Common Side Effects
● Hypoglycemia (low blood glucose level)
● Injection site reactions (pain, swelling and redness)
● Rash
● Itching
● Upper respiratory tract infections
● Liposydtrophy (skin thickening)
● Feeling Hungary
● Visual disturbances
● Sweating
Dosage And Duration
- Apidra 100IU should be taken 15 minutes before a meal or within 20 minutes after starting the meal.
- Do not stop taking without the consultation of a doctor.
- The dosage must be individualized based on the patient's blood sugar levels, meal composition and insulin requirements.
- Include the medicine with healthy diet, regular exercise, and weight reduction by taking advice to the doctor.
Mechanism Of Action
Apidra cartridge is a form of insulin that control blood sugar (glucose). The medicine helps the glucose get into the cells, so the body can use it for energy.
This is a form of hormonal therapy which lowers blood sugar within 10- 20 minutes of injecting it and effects can last for 4-5 hours. By lowering sugar level helps reduce the risk of getting any of the serious complications of diabetes such as kidney damage, eye damage and nerve problems.
Safety Advice
Faqs
Apidra 100IU cartridge is used to provide insulin to the blood sugar patients which have low and high glucose level.
References
• Mazzarino, M., Pernice, S., de la Torre, X., & Botrè, F. (2011).
A screening procedure for synthetic insulins by an HPLC-chip interfaced to a quadrupole time-of-flight mass spectrometer. In Recent advances in doping analysis (19) (pp.
148-151). Cologne: Sportverlag Straub. • Thevis, M., Thomas, A., Delahaut, P., Bosseloir, A., & Schänzer, W.
(2006). Doping control analysis of intact rapid-acting insulin analogues in human urine by liquid chromatography− tandem mass spectrometry.
Analytical chemistry, 78(6), 1897-1903. • Suárez-Casillas, P., Lora-Escobar, S. J., Montecatine-Alonso, E., Li, T., & Acosta-García, H.
(2025). Stability of thermolabile drugs at room temperature.
A review. Farmacia Hospitalaria. • Delhi, N., Delhi, N.
W., Delhi, W., Delhi, S. W., Delhi, S., & Delhi, S.
E. ONLINE SUPPLEMENTARY APPENDIX. • Dal, O.
H., & Sezer, A. D.
(2017). Analytical and Sales Data Comparison of Reference Product of Insulin Aspart and its Biosimilar in Turkey.
Marmara Pharmaceutical Journal, 21(3), 675-687. • Attjioui, H., Cheikh, A., Tebaa, A., Zerhouni, M. W., Aliat, Z., Mefetah, H., & Bouatia, M.
(2020). The rise of electronic commerce in healthcare: the need to ensure consumer safety.
Int J Pharm Sci Res, 11.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
